Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01455 (E.D. Tex. Dec. 13, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

On August 26, 2016, the Court held a hearing to address the proper construction of the disputed terms of the six patents at issue in this case, U.S. Patent Nos. 8,629,111 (“the ’111 patent”); 8,633,162 (“the ’162 patent”); 8,642,556 (“the ’556 patent”); 8,648,048 (“the ’048 patent”); 8,685,930 (“the ’930 patent”); and 9,248,191 (“the ’191 patent”). After considering the arguments made by the parties at the hearing (Dkt. No. 182), in their claim construction briefing (Dkt. Nos. 155, 165, and 171), and in their supplemental claim construction briefs (Dkt.